Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Investments Strengthen Biotechnology Cooperation

By BiotechDaily International staff writers
Posted on 16 Dec 2013
A series of new investments and cooperative agreements have strengthened the cooperation between a large Swiss/German corporation and a group of Israeli start-up biotechnology companies.

The Merck Serono (Geneva, Switzerland) Israel bioincubator complex in Yavne is set to receive two start-up biotechnology companies, Metabomed Ltd. and ChanBio Ltd. They will be joining Neviah Genomics Ltd., the first company to join the incubator, in which Merck Serono invested 10 million euros.

Metabomed is conducting research on cancer metabolism and computational biology while ChanBio will concentrate on the discovery of selective antibodies for ion channels as possible therapeutic targets for the treatment of multiple sclerosis.

Neviah Genomics was established in June 2012 by Compugen (Tel Aviv, Israel) and Merck Serono. Neviah Genomics focuses on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Merck Serono Ventures is providing the initial funding for Neviah Genomics and it will contribute its expertise in the validation and development of biomarkers for the development of a diagnostic test. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales.

Separately, Merck Serano's parent company Merck KgaA (Darmstadt, Germany) recently raised its stake in Qlight Nanotech (Jerusalem, Israel). Qlight Nanotech develops semiconductor nanocrystals that display unique optical and electrical properties. Qlight’s nanocrystals enable light conversion from UV and blue wavelengths to any other wavelength in the visible range. The color, or the wavelength, of the light is determined by the nanoparticle's size.

In addition, Merck signed a memorandum of understanding with Kadimastem Ltd. (Nes-Ziona, Israel), a developer of human pluripotent stem cell-related products, to utilize its screening platform to characterize new compounds for remyelinating agents for multiple sclerosis, and which may also help to treat amyotrophic lateral sclerosis (ALS).

"The innovative landscape of Israel fits in perfectly with our "Living Innovation" claim," said Stefan Oschmann head of pharmaceuticals at Merck. “In Israel, we not only have a past which has led to some of Merck’s most important products like Rebif and Erbitux, but also a promising future because we continue to find very interesting and cutting-edge science and the support here in Israel to translate that science into products. Israel has a quality education system and above-average intellectual capital. Compared with other countries, Israel has the highest concentration of scientists and engineers in the world. In addition, cooperation partners appreciate that Israeli scientists often work in a less conventional manner and are faster at implementing their results."

Related Links:

Merck Serono
Compugen
Qlight Nanotech




BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.